Related Experiment Video

Updated: Jun 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent

Paolo Dell'Antone1

  • 1Dipartimento di Scienze Biomediche Sperimentali, Università di Padova, Italy. paolo.dellantone@unipd.it

Medicinal Chemistry (Shariqah (United Arab Emirates))
|June 19, 2009
PubMed

Insights

3-bromopyruvate (3-BrPA) inhibits energy production by targeting glyceraldehyde 3-phosphate dehydrogenase and ATP synthesis in normal cells. This leads to a significant decrease in ATP levels, suggesting potential therapeutic applications.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • 3-bromopyruvate (3-BrPA) is a pyruvate analog explored for anticancer properties.
  • Its mechanism of action, particularly regarding energy metabolism inhibition, requires further elucidation.

Purpose of the Study:

  • To investigate the effects of 3-bromopyruvate on energy production in normal cellular systems.
  • To identify the specific molecular targets of 3-bromopyruvate in energy metabolism.

Main Methods:

  • Enzyme activity assays were performed on cellular fractions from rat hepatocytes.
  • ATP levels were measured in isolated rat thymocytes.
  • The drug's impact on succinate-driven ATP synthesis was assessed.

Main Results:

  • 3-bromopyruvate was found to inhibit glyceraldehyde 3-phosphate dehydrogenase, not hexokinase.
  • The drug significantly inhibited succinate-driven ATP synthesis.
  • A notable reduction in ATP levels was observed in thymocytes treated with 3-BrPA.

Conclusions:

  • 3-bromopyruvate targets key enzymes in glycolysis and ATP synthesis in normal cells.
  • The observed inhibition of energy production in normal cells warrants consideration for its therapeutic potential.
  • Further studies are needed to fully understand the implications for anticancer drug development.

More Related Videos

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...